N@N

Kevin Caliendo Maintained (TEVA) at Strong Buy with Increased Target to $15 on, May 11th, 2020

Kevin Caliendo of UBS, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Strong Buy with Increased Target from $12 to $15 on, May 11th, 2020.

Kevin has made no other calls on TEVA in the last 4 months.

There are 7 other peers that have a rating on TEVA. Out of the 7 peers that are also analyzing TEVA, 4 agree with Kevin's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• David Amsellem of "Piper Sandler" Maintained at Hold with Decreased Target to $8 on, Wednesday, April 15th, 2020
• Jacob Hughes of "Wells Fargo" Maintained at Hold with Increased Target to $12 on, Thursday, March 5th, 2020
• Louise Chen of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $15 on, Wednesday, February 12th, 2020
• Sel Hardy of "CFRA" Maintained at Hold with Increased Target to $13 on, Wednesday, February 12th, 2020

These are the ratings of the 3 analyists that currently disagree with Kevin

---

• Jason Gerberry of "B of A Securities" Reiterated at Sell with Increased Target to $8 on, Friday, May 8th, 2020
• David Risinger of "Morgan Stanley" Maintained at Sell with Decreased Target to $8 on, Thursday, April 2nd, 2020
• Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $16 on, Thursday, February 13th, 2020

Contributing Sources

---